MYGN241220P13000
- 0.55
- 0.000.00%
Myriad Genetics Newsroom
Morgan Stanley Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $21
Scotiabank Maintains Myriad Genetics(MYGN.US) With Buy Rating, Cuts Target Price to $24
Myriad Genetics Is Maintained at Neutral by Piper Sandler
Myriad Genetics Analyst Ratings
J.P. Morgan Maintains Myriad Genetics(MYGN.US) With Sell Rating, Cuts Target Price to $15
Piper Sandler Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $24
Analysts Offer Insights on Healthcare Companies: Myriad Genetics (MYGN) and Jazz Pharmaceuticals (JAZZ)
TD Cowen Maintains Myriad Genetics(MYGN.US) With Hold Rating, Maintains Target Price $20
TD Cowen Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $20
Cautious Hold Recommendation for Myriad Genetics Amid GeneSight Coverage Challenges and Mixed Revenue Signals
TD Cowen Maintains Myriad Genetics(MYGN.US) With Hold Rating, Maintains Target Price $30
TD Cowen Reaffirms Their Hold Rating on Myriad Genetics (MYGN)
Morgan Stanley Maintains Myriad Genetics(MYGN.US) With Hold Rating, Maintains Target Price $32
Scotiabank Maintains Myriad Genetics(MYGN.US) With Buy Rating, Maintains Target Price $34
Stephens Maintains Myriad Genetics(MYGN.US) With Hold Rating, Raises Target Price to $30
A Quick Look at Today's Ratings for Myriad Genetics(MYGN.US), With a Forecast Between $32 to $40
Scotiabank Keeps Their Buy Rating on Myriad Genetics (MYGN)
Steady Growth and Market Stability Justify Hold Rating for Myriad Genetics
Wells Fargo Maintains Myriad Genetics(MYGN.US) With Buy Rating, Maintains Target Price $35
Myriad Genetics: A Buy Rating Amid Reaffirmed Strategy and Growth Potential